Share:
TAIPEI and SAN DIEGO, Dec. 23. 2020 /PRNewswire/ Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that it has received a Study May Proceed letter from the US Food and Drug Administration (FDA) to begin a Phase Ib study evaluating CX-5461, a first-in-class G-quadruplex stabilizer, to treat solid tumors with
BRCA2 or PALB2 mutations. The FDA s approval of our Phase Ib clinical trial application for testing CX-5461 in patients with
BRCA2 or PALB2 mutations is an important milestone and marks a new paradigm in the treatment of cancers with specific pathogenic mutations, stated Dr. John Soong, the Chief Medical Officer of Senhwa Biosciences.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Senhwa Biosciences’s Positive Topline Cholangiocarcinoma Data Abstract Accepted by 2021 ASCO Gastrointestinal Cancers Symposium
December 14, 2020 GMT
TAIPEI and SAN DIEGO, Dec. 13, 2020 /PRNewswire/ Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, announced their Abstract on Cholangiocarcinoma treatment with Silmitasertib (CX-4945) has been accepted for oral/poster presentation at the upcoming American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, 15-17 January, 2021. Due to the COVID-19 pandemic, the event will be hosted virtually.